Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies

被引:16
作者
Pirez, Maria Catalina [2 ]
Olivera, Ignacio [2 ]
Diabarboure, Hugo [3 ]
Montano, Alicia [2 ]
Baranano, Raul [4 ]
Badia, Federica [2 ]
Bonnet, Marie-Claude [1 ]
机构
[1] Sanofi Pasteur, Global Sci & Med Affairs, Lyon, France
[2] Univ Republica, Sch Med, Montevideo, Uruguay
[3] Labs Clausen, Montevideo, Uruguay
[4] Clin Medilab, Montevideo, Uruguay
关键词
Oral polio vaccine; Antibody persistence; Seroprevalence; Vaccination coverage; NEUTRALIZING ANTIBODIES; IMMUNITY STATUS; POLIOMYELITIS; POLIOVIRUSES; IMMUNIZATION; ERADICATION; DIPHTHERIA; PERTUSSIS; TETANUS; INFANTS;
D O I
10.1016/j.vaccine.2009.02.042
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study evaluated the seroprevalence of poliovirus types 1, 2 and 3 antibodies and vaccination coverage in 780 subjects aged between 7 months and 39 years in Montevideo, Uruguay, where oral polio vaccine (CPV) is used. Antibody titers were measured and seroprotection rates and geometric mean titers (GMTs) were compared among four age groups. Vaccination histories were recorded from documents and interviews. Seroprotection rates ranged from 72% to 95% in children aged 7-23 months, 31-77% in 2-9-year olds, 14-45% in 10-19-year olds and 20-59.5% in 20-39-year olds. Seroprotection decreased significantly with increasing age (p<0.05). Polio vaccination coverage was >90% for the two youngest age groups. These results could help guide public policy decisions regarding polio vaccination, and support the use of inactivated polio vaccine following cessation of OPV. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2689 / 2694
页数:6
相关论文
共 35 条
  • [11] World wide experience with inactivated poliovirus vaccine
    Bonnet, Marie-Claude
    Dutta, Anil
    [J]. VACCINE, 2008, 26 (39) : 4978 - 4983
  • [12] Caidi H, 2004, East Mediterr Health J, V10, P474
  • [13] CARDENAS ARY, 2007, ARCH INVEST PEDIAT M, V10, P3
  • [14] Serologic response to inactivated poliovirus vaccine:: A randomized clinical trial comparing 2 vaccination schedules in Puerto Rico
    Dayan, Gustavo H.
    Thorley, Margaret
    Yamamura, Yasuhiro
    Rodriguez, Nayra
    McLaughlin, Steve
    Torres, Lourdes M.
    Seda, Antonio
    Carbia, Marcia
    Alexander, Lorraine N.
    Caceres, Victor
    Pallansch, Mark A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (01) : 12 - 20
  • [15] A seroprevalence study of poliovirus antibody in the population of northern Greece
    Frantzidou, F
    Diza, E
    Halkia, D
    Antoniadis, A
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (01) : 68 - 71
  • [16] Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba
    Galindo, Miguel
    Lago, Pedro Mas
    Caceres, Victor
    Landaverde, Mauricio
    Sutter, Roland
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) : 1536 - 1544
  • [17] IMMUNE-RESPONSE TO MEASLES AND SMALLPOX VACCINATIONS IN MALNOURISHED CHILDREN
    IFEKWUNIGWE, AE
    GRASSET, N
    GLASS, R
    FOSTER, S
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1980, 33 (03) : 621 - 624
  • [18] Vaccine-derived polioviruses and the endgame strategy for global polio eradication
    Kew, OM
    Sutter, RW
    de Gourville, EM
    Dowdle, WR
    Pallansch, MA
    [J]. ANNUAL REVIEW OF MICROBIOLOGY, 2005, 59 : 587 - 635
  • [19] Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants
    Lagos, R
    Kotloff, K
    Hoffenbach, A
    San Martin, O
    Abrego, P
    Ureta, AM
    Pines, E
    Blondeau, C
    Bailleux, F
    Levine, MM
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (04) : 294 - 304
  • [20] Lamy M E, 1979, Dev Biol Stand, V43, P207